Vireo Growth Inc.

VREOFSEC EDGAR

Pharmaceutical Preparations(A1)CIK: 1771706

Concept	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$88.1M	$74.6M	$54.4M	$49.2M
Cost of Goods and Services Sold	—	—	$32.0M	$31.1M
Gross Profit	$44.1M	$30.9M	$19.8M	$17.1M
Selling, General and Administrative Expense	$28.2M	$33.8M	$33.7M	$26.4M
Operating Expenses	$33.5M	$37.8M	$40.3M	$40.2M
Operating Income (Loss)	$10.6M	-$6.9M	-$20.5M	-$23.0M
Interest Expense	—	$22.6M	$10.6M	$5.1M
Nonoperating Income (Expense)	-$28.4M	-$29.6M	-$9.1M	$8.9M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$183.3M	$159.2M	$167.0M	$102.6M
Assets, Current	$148.9M	$46.7M	$41.6M	$47.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$2.3M	$4.3M	$4.5M	$697.0K
Inventory, Net	$19.3M	$20.5M	$20.4M	$12.6M
Liabilities	$199.3M	$155.7M	$124.0M	$40.3M
Liabilities, Current	$179.5M	$29.7M	$16.4M	$19.9M
Long-term Debt	—	—	$1.1M	$1.1M
Stockholders' Equity Attributable to Parent	$3.4M	$43.0M	$62.3M	$48.7M
Weighted Average Number of Shares Outstanding, Basic

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$965.9K	-$18.1M	-$30.5M	-$10.9M
Net Cash Provided by (Used in) Investing Activities	-$3.5M	-$5.6M	-$7.2M	$12.9M
Net Cash Provided by (Used in) Financing Activities	$5.3M	$23.7M	$25.8M	$15.9M
Payments to Acquire Property, Plant, and Equipment	$5.0M	$5.6M	$18.0M	$8.4M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)